Pfizer CFO Dave Denton departing Aug 15 for consumer goods role; Cecile Guegan named Interim CFO

Filed June 18, 2026 · Period ending June 18, 2026 · ~1 min read

Key Changes

• high

  CFO Dave Denton stepping down effective August 15, 2026 to pursue opportunity in consumer goods industry. Company states departure unrelated to financial results or disagreements on accounting/reporting.

  Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation verify on EDGAR →
• high

  Cecile Guegan, Senior VP Finance for Global Biopharmaceutical Business, will serve as Interim CFO starting August 16, 2026 while Pfizer searches for permanent successor.

  Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation verify on EDGAR →
• medium

  Guegan brings 21 years at Pfizer with finance leadership roles including VP Finance for R&D (2020-2022) and current role since 2022, providing continuity during transition.

  Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation verify on EDGAR →